| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MLN4924 | GDSC1000 | pan-cancer | AAC | 0.013 | 0.7 |
| mRNA | GW-405833 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | BRD-K41597374 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | -0.016 | 0.8 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | shikonin | GDSC1000 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |